AMENDMENTS TO THE CLAIMS

The listing of the claims replaces all prior versions and listings of the claims for this application. Within this listing of the claims, claims 30-33, 35, 36, and 40-44 are newly canceled.

- 1. (previously presented) A method for treating a patient suffering from or predisposed to developing interstitial lung disease (ILD), comprising administering to the patient a pharmaceutical formulation that comprises a pharmaceutically acceptable carrier and a therapeutically effective amount of an active agent selected from the group consisting of resveratrol, pharmacologically acceptable salts, esters, amides, prodrugs or analogs thereof, and combinations of any of the foregoing.
- 2. **(original)** The method of claim 1, wherein the active agent is *cis*-resveratrol or a pharmacologically acceptable salt, ester, amide, prodrug or analog thereof.
 - 3. **(original)** The method of claim 2, wherein the active agent is *cis*-resveratrol.
- 4. **(original)** The method of claim 2, wherein the active agent is a conjugate of *cis*-resveratrol and a mono- or di-saccharide.
 - 5. (original) The method of claim 4, wherein the active agent is cis-resveratrol glucoside.
- 6. **(original)** The method of claim 1, wherein the active agent is *trans*-resveratrol or a pharmacologically acceptable salt, ester, amide, prodrug or analog thereof.
 - 7. (original) The method of claim 6, wherein the active agent is *trans*-resveratrol.
- 8. (original) The method of claim 6, wherein the active agent is a conjugate of *trans*-resveratrol and a mono- or di-saccharide.
 - 9. (original) The method of claim 8, wherein the active agent is *trans*-resveratrol glucoside.
- 10. (original) The method of claim 1, wherein the active agent comprises a mixture of *cis*-resveratrol and *trans*-resveratrol.

- 11. (original) The method of claim 1, wherein the active agent is delivered orally.
- 12. (original) The method of claim 1, wherein the active agent is delivered by pulmonary administration.
 - 13. (original) The method of claim 1, wherein the active agent is delivered parenterally.
 - 14. (original) The method of claim 13, wherein the active agent is delivered to the alveoli.
 - 15-23. (canceled)
- 24. (original) The method of claim 1, further comprising the co-administration of an additional active agent.
- 25. (original) The method of claim 24, wherein the formulation further includes an additional active agent.
- 26. (original) The method of claim 25, wherein the additional active agent is selected from the group consisting of glucocorticoids, non-steroidal antiinflammatory drugs, macrolide antibiotics, bronchodilators, leukotriene receptor inhibitors, cromolyn sulfate and combinations thereof.
- 27. (previously presented) The method of claim 26, wherein the additional active agent is selected from the group consisting of phosphodiesterase inhibitors, long acting β_2 adrenergic agonists, and combinations thereof.
- 28. (original) The method of claim 27, wherein the additional active agent is selected from the group consisting of theophylline, salmetrol xinafoate, and a combination thereof.

29-37. (canceled)

38. (previously presented) The method of claim 1, wherein the ILD is fibrosing alveolitis, sarcoidiosis, or fibrotic lung disease.

Application No. 09/694,108 Amendment dated August 9, 2004 Reply to Final Office Action of May 21, 2004

39-44. (canceled)